No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - August 13, 2026 78 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENDURANCE study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... November 3, 2025 What Are Multi-Cancer Early Detection Tests and How Might They Impact... October 25, 2022 Cancer services during COVID-19: 40,000 fewer people starting treatment February 2, 2021 How Being an Athlete Prepared Me for My Cancer Experience August 9, 2022 Load more HOT NEWS Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated... The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer Study Finds Possible New Treatment for Metastatic Breast Cancer That Has...
